UniProt ID | UBE2N_HUMAN | |
---|---|---|
UniProt AC | P61088 | |
Protein Name | Ubiquitin-conjugating enzyme E2 N | |
Gene Name | UBE2N | |
Organism | Homo sapiens (Human). | |
Sequence Length | 152 | |
Subcellular Localization | Nucleus . Cytoplasm . | |
Protein Description | The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of non-canonical 'Lys-63'-linked polyubiquitin chains. This type of polyubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Acts together with the E3 ligases, HLTF and SHPRH, in the 'Lys-63'-linked poly-ubiquitination of PCNA upon genotoxic stress, which is required for DNA repair. Appears to act together with E3 ligase RNF5 in the 'Lys-63'-linked polyubiquitination of JKAMP thereby regulating JKAMP function by decreasing its association with components of the proteasome and ERAD. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes.. | |
Protein Sequence | MAGLPRRIIKETQRLLAEPVPGIKAEPDESNARYFHVVIAGPQDSPFEGGTFKLELFLPEEYPMAAPKVRFMTKIYHPNVDKLGRICLDILKDKWSPALQIRTVLLSIQALLSAPNPDDPLANDVAEQWKTNEAQAIETARAWTRLYAMNNI | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MAGLPRRII ------CCCCCHHHH | 28.38 | - | |
10 | Acetylation | GLPRRIIKETQRLLA CCCHHHHHHHHHHHC | 52.95 | 21791702 | |
10 | Ubiquitination | GLPRRIIKETQRLLA CCCHHHHHHHHHHHC | 52.95 | 21890473 | |
24 | Ubiquitination | AEPVPGIKAEPDESN CCCCCCCCCCCCCCC | 53.24 | 21890473 | |
24 | Sumoylation | AEPVPGIKAEPDESN CCCCCCCCCCCCCCC | 53.24 | - | |
24 | Acetylation | AEPVPGIKAEPDESN CCCCCCCCCCCCCCC | 53.24 | 23236377 | |
34 | Phosphorylation | PDESNARYFHVVIAG CCCCCCCEEEEEEEC | 8.81 | 28152594 | |
45 | Phosphorylation | VIAGPQDSPFEGGTF EEECCCCCCCCCCEE | 26.66 | - | |
53 | Acetylation | PFEGGTFKLELFLPE CCCCCEEEEEEECCC | 40.67 | 7960459 | |
64 | Sulfoxidation | FLPEEYPMAAPKVRF ECCCCCCCCCCCEEE | 4.93 | 30846556 | |
68 | Ubiquitination | EYPMAAPKVRFMTKI CCCCCCCCEEEEECC | 41.12 | 21906983 | |
68 | 2-Hydroxyisobutyrylation | EYPMAAPKVRFMTKI CCCCCCCCEEEEECC | 41.12 | - | |
74 | 2-Hydroxyisobutyrylation | PKVRFMTKIYHPNVD CCEEEEECCCCCCHH | 29.49 | - | |
74 | Acetylation | PKVRFMTKIYHPNVD CCEEEEECCCCCCHH | 29.49 | 23236377 | |
74 | Ubiquitination | PKVRFMTKIYHPNVD CCEEEEECCCCCCHH | 29.49 | 21890473 | |
76 | Nitration | VRFMTKIYHPNVDKL EEEEECCCCCCHHHH | 16.87 | - | |
76 | Phosphorylation | VRFMTKIYHPNVDKL EEEEECCCCCCHHHH | 16.87 | 28152594 | |
82 | Malonylation | IYHPNVDKLGRICLD CCCCCHHHHHHHHHH | 48.86 | 26320211 | |
82 | 2-Hydroxyisobutyrylation | IYHPNVDKLGRICLD CCCCCHHHHHHHHHH | 48.86 | - | |
82 | Ubiquitination | IYHPNVDKLGRICLD CCCCCHHHHHHHHHH | 48.86 | 21890473 | |
82 | Acetylation | IYHPNVDKLGRICLD CCCCCHHHHHHHHHH | 48.86 | 19608861 | |
87 | Glutathionylation | VDKLGRICLDILKDK HHHHHHHHHHHHCCC | 2.42 | 22555962 | |
87 | S-nitrosylation | VDKLGRICLDILKDK HHHHHHHHHHHHCCC | 2.42 | 22178444 | |
87 | S-nitrosocysteine | VDKLGRICLDILKDK HHHHHHHHHHHHCCC | 2.42 | - | |
92 | Succinylation | RICLDILKDKWSPAL HHHHHHHCCCCCHHH | 58.56 | 23954790 | |
92 | Ubiquitination | RICLDILKDKWSPAL HHHHHHHCCCCCHHH | 58.56 | 21890473 | |
92 | Acetylation | RICLDILKDKWSPAL HHHHHHHCCCCCHHH | 58.56 | 21791702 | |
94 | Ubiquitination | CLDILKDKWSPALQI HHHHHCCCCCHHHHH | 48.24 | 21890473 | |
94 | Acetylation | CLDILKDKWSPALQI HHHHHCCCCCHHHHH | 48.24 | 21791702 | |
96 | Phosphorylation | DILKDKWSPALQIRT HHHCCCCCHHHHHHH | 13.16 | 28857561 | |
139 | Phosphorylation | NEAQAIETARAWTRL CHHHHHHHHHHHHHH | 18.48 | - | |
141 | Methylation | AQAIETARAWTRLYA HHHHHHHHHHHHHHH | 37.77 | - | |
144 | Phosphorylation | IETARAWTRLYAMNN HHHHHHHHHHHHHHC | 15.15 | - | |
145 | Methylation | ETARAWTRLYAMNNI HHHHHHHHHHHHHCC | 18.26 | 115919365 | |
147 | Phosphorylation | ARAWTRLYAMNNI-- HHHHHHHHHHHCC-- | 10.66 | - |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of UBE2N_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of UBE2N_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of UBE2N_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY. | |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-10; LYS-82 AND LYS-94, ANDMASS SPECTROMETRY. |